Medicine for improving state of pregnancy, and use thereof

Abstract

A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.

1 . A medicine for ameliorating pregnancy conditions, the medicine comprising a compound represented by the following General Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: 
       
         
           
           
               
               
           
         
         wherein each of the adjacent pairs of R 1  with R 2 , R 3  with R 4 , and R 5  with R 6  independently 
         (a) represents two adjacent hydrogen atoms, or R 2  may be an alkyl group, or 
         (b) may form another bond between the carbon atoms to which the pair members are respectively bonded; 
         R 7  represents a hydrogen atom, a hydroxyl group, or a protected hydroxyl group, or may be bonded to an alkyl and together represent an oxo group; 
         R 8  and R 9  each independently represent a hydrogen atom or a hydroxyl group; 
         R 10  represents a hydrogen atom, an alkyl group, an alkyl group substituted with one or more hydroxyl groups, an alkenyl group, an alkenyl group substituted with one or more hydroxyl groups, or an alkyl group substituted with an oxo group; 
         X represents an oxo group, (a hydrogen atom, a hydroxyl group), (a hydrogen atom, a hydrogen atom), or a group represented by formula: —CH 2 O—; 
         Y represents an oxo group, (a hydrogen atom, a hydroxyl group), (a hydrogen atom, a hydrogen atom), or a group represented by formula: N—NR 11 R 12  or formula: N—OR 13 ; 
         R 11  and R 12  each independently represent a hydrogen atom, an alkyl group, an aryl group, or a tosyl group; 
         R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 22 , and R 23  each independently represent a hydrogen atom or an alkyl group; 
         R 24  represents a ring which can include one or more heteroatoms and may be substituted as desired; and 
         n represents 1 or 2, and 
         in addition to the meanings described above, Y, R 10  and R 23  may also be bonded together with the carbon atoms to which Y, R 10  and R 23  are bonded, and represent a heterocyclic group formed from a saturated or unsaturated 5-membered or 6-membered ring and containing a nitrogen atom, a sulfur atom, and/or an oxygen atom, and the heterocyclic group may be substituted with one or more groups selected from an alkyl group, a hydroxyl group, an alkyloxy group, a benzyl group, a group represented by formula: —CH 2 Se(C 6 H 5 ), and an alkyl group substituted with one or more hydroxyl groups. 
       
     
     
         2 . The medicine according to  claim 1 , wherein the compound is tacrolimus or a pharmaceutic ally acceptable salt thereof. 
     
     
         3 . The medicine according to  claim 1 , wherein the medicine ameliorates defective pregnancy conditions attributed to immunological abnormalities. 
     
     
         4 . The medicine according to  claim 1 , wherein the medicine ameliorates at least one defective pregnancy condition selected from the group consisting of sterility, infertility, and pregnancy-induced hypertension syndrome. 
     
     
         5 . The medicine according to  claim 1 , wherein the medicine is administered to a subject of treatment at a dose of 5 mg or less per day as the amount of the active ingredient. 
     
     
         6 . The medicine according to  claim 5 , wherein the amount of the active ingredient is in the range of from 1 mg to 3 mg per day. 
     
     
         7 . The medicine according to  claim 1 , wherein the medicine is administered to a subject having an increased Th1/Th2 cell ratio compared to a normal person. 
     
     
         8 . The medicine according to  claim 1 , wherein the medicine is administered to a subject who is subjected to transplantation of an embryo obtained by in vitro fertilization. 
     
     
         9 . The medicine according to  claim 1 , wherein in a case in which the medicine is intended for sterility as a defective pregnancy condition, the medicine is administered at least during a period from 1 day before or 2 days before the implantation of a fertilized ovum or a transplanted embryo into the endometrium, to 0 days after the implantation; and in a case in which the medicine is intended for a defective pregnancy condition other than sterility, the medicine is administered at least for a period from the establishment to the 200th day of pregnancy.